Devita, Hellman, and Rosenberg's Cancer

LWBK1006-02 LWW-Govindan-Review November 24, 2011 11:18

22 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 2.32. Which of the following is NOT thought to be a mechanism of antiangio-

genic treatment resistance?

A. Decreased penetration of antiangiogenic molecules into tumor cells

B. Selection of hypoxia resistant cells

C. Vascular remodeling

D. Proangiogenic growth factor redundancy

Question 2.33. Which of the following is NOT an associated potential toxicity of antian-

giogenic therapy?

A. Hypertension

B. Aplastic anemia

C. Bowel perforation

D. Arteriothrombotic event

Question 2.34. Which of the following is NOT associated with a risk of metastasis?

A. Tumor grade

B. Depth of invasion beyond normal cellular compartments

C. Lymphovascular invasion

D. Proper immune function

Question 2.35. What percentage of tumor cells can give rise to metastases?

A. <0.01%

B. 1%

C. 20%

D. >80%

Question 2.36. Genes that can mediate tumorigenic functions and secondarily serve

metastatic-specific functions either in a general way or with particular

organ selectivity are best known as:

A. Tumorigenic genes

B. Metastasis progression genes

C. Metastasis virulence genes

D. Protooncogenes

Question 2.37. Cells that mediate the breakdown of the basement membrane allowing

for tumor invasion are known as:

A. Carcinoma-associated fibroblasts

B. Pericyte-derived fibroblast

C. Tumor-associated macrophages (TAMs)

D. Dendritic cells

Question 2.38. Cellular loss of this molecule leads to decreased cellular attachment and

enhanced tumor invasion/motility:

A. E-cadherin

B. -catenin

C. -tubulin

D. Ankrin